Brian P. Mckeon Sells 23,326 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Free Report) CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $572.21 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $579.68. The firm has a market capitalization of $47.52 billion, a price-to-earnings ratio of 56.82, a price-to-earnings-growth ratio of 3.16 and a beta of 1.25. The business has a 50 day simple moving average of $540.92 and a 200 day simple moving average of $491.38. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.02.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $2.05 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.08 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. The Goldman Sachs Group raised their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $591.50.

Check Out Our Latest Report on IDEXX Laboratories

Institutional Investors Weigh In On IDEXX Laboratories

Large investors have recently modified their holdings of the stock. Atria Wealth Solutions Inc. boosted its stake in shares of IDEXX Laboratories by 33.9% during the 2nd quarter. Atria Wealth Solutions Inc. now owns 5,134 shares of the company’s stock worth $2,578,000 after acquiring an additional 1,300 shares in the last quarter. NewEdge Wealth LLC boosted its stake in shares of IDEXX Laboratories by 30.4% during the 3rd quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock worth $279,000 after acquiring an additional 149 shares in the last quarter. Mitchell Capital Management Co. lifted its holdings in shares of IDEXX Laboratories by 1.3% in the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after purchasing an additional 79 shares in the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in shares of IDEXX Laboratories by 3.1% in the second quarter. Linden Thomas Advisory Services LLC now owns 4,846 shares of the company’s stock valued at $2,434,000 after purchasing an additional 144 shares in the last quarter. Finally, EA Series Trust purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $278,000. 86.85% of the stock is owned by institutional investors.

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Recommended Stories

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.